Proquimes S A Productos Quimicos Especializados S.A. Warning Letter Details

Summary

Proquimes S.A., a pharmaceutical chemical manufacturer, received a Warning Letter from the FDA's Center for Drug Evaluation and Research on April 5, 2021, regarding Current Good Manufacturing Practice (CGMP) violations and adulteration issues related to Active Pharmaceutical Ingredients (APIs). The violations indicate that the company's manufacturing processes, controls, or documentation for drug ingredients did not meet FDA standards, potentially affecting the quality and safety of drugs produced with these materials. Based on the available metadata alone, specific details about the nature or scope of the adulteration cannot be determined without review of the full letter text.